Geftib 250mg Tablet

1. Product Introduction:

Geftib 250mg Tablet is a targeted cancer therapy containing Gefitinib, a tyrosine kinase inhibitor (TKI) specifically used in the treatment of non-small cell lung cancer (NSCLC). Gefitinib is an oral anti-cancer medication that works by blocking the activity of a protein called epidermal growth factor receptor (EGFR), which is responsible for the growth and survival of cancer cells.

The medication is particularly effective in patients whose cancer cells show mutations in the EGFR gene, making it a precision treatment with higher efficacy and fewer side effects than traditional chemotherapy in these cases. Geftib is usually prescribed to patients with locally advanced or metastatic NSCLC and is often used as a first-line treatment when EGFR mutations are confirmed.

2. Uses of This Medicine:

Geftib 250mg Tablet is mainly used for:

• Treatment of Non-Small Cell Lung Cancer (NSCLC):
  It is indicated for patients with advanced or metastatic NSCLC with EGFR gene mutations.

• First-Line Therapy:
  Used as the first-line treatment in newly diagnosed patients with EGFR mutation-positive NSCLC.

• Maintenance Therapy:
  May also be used as a maintenance therapy after initial chemotherapy in certain cases.

• Second-Line or Third-Line Treatment:
  Administered when previous lines of treatment have failed, and the tumor continues to express EGFR mutations.

3. Benefits of This Medicine:

• Targeted Therapy:
  Geftib directly targets and inhibits the EGFR tyrosine kinase, thereby preventing the growth of cancer cells.

• Improved Quality of Life:
  Compared to conventional chemotherapy, Gefitinib is associated with fewer side effects and can often be taken at home, improving patient convenience and comfort.

• Effective in EGFR-Mutated Tumors:
  Patients with EGFR-positive tumors often experience significant tumor shrinkage and improved survival outcomes.

• Oral Administration:
  Being a tablet, it removes the need for hospital-based intravenous administration, making the treatment more accessible and manageable.

• Prolongs Progression-Free Survival:
  In EGFR-positive patients, Geftib can delay disease progression for several months longer than chemotherapy.

• Tolerable Side Effect Profile:
  Most patients tolerate Gefitinib well with side effects that are generally milder than those caused by chemotherapy.

4. Side Effects:

While Geftib 250mg Tablet is generally well-tolerated, it may cause some side effects. Patients should be monitored regularly during treatment.

Common Side Effects:

• Skin rash and dry skin

• Diarrhea

• Nausea

• Vomiting

• Fatigue

• Loss of appetite

• Stomatitis (mouth ulcers)

Less Common but Serious Side Effects:

• Interstitial lung disease (rare but serious lung inflammation)

• Elevated liver enzymes (requires liver function monitoring)

• Eye irritation or inflammation

• Severe skin reactions in some individuals

Note: Inform your doctor immediately if you experience persistent coughing, difficulty breathing, yellowing of the skin or eyes, or signs of infection.

5. Frequently Asked Questions (FAQ):

Q1. What is Geftib 250mg Tablet used for?
A: It is used to treat non-small cell lung cancer (NSCLC) that is locally advanced or has spread to other parts of the body, particularly when the tumor has EGFR mutations.

Q2. How does Gefitinib work?
A: Gefitinib blocks the EGFR protein, which helps stop cancer cells from growing and multiplying.

Q3. How should I take Geftib 250mg Tablet?
A: Take the tablet once daily, with or without food, as prescribed by your doctor. Do not crush or chew the tablet.

Q4. Can I stop taking Geftib if I feel better?
A: No. You should continue taking the medication for as long as prescribed, even if symptoms improve. Stopping early may cause the cancer to return or progress.

Q5. Are there any dietary restrictions while using this medicine?
A: Avoid grapefruit and grapefruit juice, as they may increase drug levels in the blood and lead to increased side effects. Always consult your doctor about other food or drug interactions.